ExAblate 4000 Type 2.1 for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Jun 2024: Trial registered, NCT06474013

The trials

NCT06474013: A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease

State
State not given
Phase
No phase
People
15 planned
Started
1 Sep 2024
Primary completion
30 Sep 2024
Arms
Blood Brain Barrier (BBB) Disruption
Results
None posted
  1. 25 Jun 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Device.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.